Anti-Ri paraneoplastic syndrome associated with ophtalmoplegia, blepharospasm and palilalia;Ophtalmoplégie, blépharospasme et palilalie associés à des anticorps anti-Ri

Revue Neurologique

Volumn 161, Issue 1, 2005, Pages 81-86

  Martinaud, O ^a   Guegan Massardier, E ^a   Iasci, L ^a   Miret, N ^a   Mihout, B ^a   Hannequin, D ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Blepharospasm; Breast cancer; Ophtalmoplegia; Palilalia; Paraneoplastic syndrome; Ri

Indexed keywords

ANTINEOPLASTIC AGENT; CELL ANTIBODY; CYCLOPHOSPHAMIDE; EPIRUBICIN; HU ANTIBODY; IMMUNOGLOBULIN; RI ANTIBODY; UNCLASSIFIED DRUG; YO ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ATAXIA; BLEPHAROSPASM; BREAST ADENOCARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG INFUSION; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MYOCLONUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OPHTHALMOPLEGIA; OPSOCLONUS; OUTCOMES RESEARCH; PALILALIA; PARANEOPLASTIC SYNDROME; SYMPTOM;

EID: 13244257149     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(05)84978-1     Document Type: Article

References (29)

1. th edition. NewYork: MacGraw Hill, 1997: p. 105.
2. BATALLER L, GRAUS F, SAIZ A, VILCHEZ JJ. SPANISH OPSOCLONUS-MYOCLONUS STUDY GROUP. (2001). Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain, 124: 437-443.
3. BERTHOZ A. (1997). L'exploration visuelle. Dans: Le sens du mouvement. Odile Jacob (Ed). p. 214-219.
4. BUDDE-STEFFEN C, ANDERSON NE, ROSENBLUM MK et al. (1988). An anti-neuronal autoantibody in paraneoplastic opsoclonus. Ann Neurol, 23: 528-531.
5. CAMERLINGO M, NEMNI R, FERRARO B, CASTO L, PARTZIGUIAN T, CENSORI B, MAMOLI A. (1998). Malignancy and sensory neuropathy of unexplained cause. Arch Neurol, 55: 981-984.
6. DROPCHO EJ, KLINE LB, RISER J. (1993). Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology, 43: 207-211.
7. ENDERLE JD. (2002). Neural control of saccades. Prog Brain Res, 140: 21-49.
8. ESCUDERO D, BARNADAS A, CODINA M, FUEYO J, GRAUS F. (1993). Anti-Ri associated paraneoplastic neurological disorder without opsoclonus in a patient with breast cancer. Neurology, 43: 1605-1606.
9. HORMIGO A, DALMAU J, ROSENBLUM MK, RIVER ME, POSNER JB. (1994). Immunological and pathological study of anti-Ri associated encephalopathy. Ann Neuro, 36: 896-902.
10. JANKOVIC J, PATEL SC. (1983). Blepharospasm associated with brainstem lesions. Neurology, 33: 1237-1240.
11. JANKOVIC J. (1985). Progressive supranuclear palsy: paraneoplastic effect of bronchial carcinoma. Neurology, 35: 446-447.
12. JONGEN JL, MOLL WJ, SILLEVIS SMITT PA, VECHT CJ, TIJSSEN CC. (1998). Anti-Ri positive opsoclonus-myoclonus-ataxia in ovarian duct cancer. J Neurol, 245: 691-692.
13. KANZATO N, MOTOMURA M, SUEHARA M, ARIMURA K. (1999). Lambert-Eaton myasthenic syndrome with ophtalmoparesis and pseudoblepharospasm. Muscle Nerve, 22: 1727-1730.
14. KASTRUP O, MEYRING S, DIENER HC. (2001). Atypical paraneoplastic brainstem encephalitis associated with anti-Ri antibodies due to thymic carcinoma with possible response to immunoglobulins. Eur Neurol, 45: 285-287.
15. KIKUCHI H, YAMADA T, OKAYAMA A et al. (2000). Anti-Ri-associated paraneoplastic cerebellar degeneration without opsoclonus in a patient with a neuroendocrine carcinoma of the stomach. Fukuoka Igaku Zasshi, 91: 104-109.
16. LUQUE FA, FURNEAUX HM, FERZIGER R et al. (1991). Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol, 29: 241-251.
17. MACIA F, BALLAN G, YEKHLEF F, DELMER O, VITAL C, LAGUENY A, TISON F. (2003). Paralysie supranucléaire progressive: étude clinique, histoire naturelle et progression du handicap. Rev Neurol (Paris), 159: 31-42.
18. OHMER R, GOLNIK KC, RICHARDS AI, KOSMORSKY GS. (1999). Ophthalmoplegia associated with the anti-Ri antibody. J Neuroophtalmol, 19: 246-248.
19. PITTOCK S, LUCCHINETTI C, LENNON V. (2003). Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol, 53: 580-587.
20. POSNER JB. (2002). Les syndromes paranéoplasiques (anglais). Rev Neurol (Paris), 158: 899-906.
21. PRESTIGIACOMO CJ, BALMACEDA C, DALMAU J. (2001). Anti-Ri associated paraneoplastic opsoclonus-ataxia syndrom in a man with transitionnal cell carcinoma. Cancer, 91: 1423-1428.
22. ROJAS-MARCOS I, ROUSSEAU A, KEIME-GUIBERT F et al. (2003). Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore), 82: 216-223.
23. SHAMS'ILI S, GREFKENS J, DE LEEUW B et al. (2003). Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain, 126: 1409-1418.
24. SCHMIDT KE, LINDEN DE, GOEBEL R, ZANELLA FE, LANFERMANN H, ZUBCOV AA. (2003). Striatal activation during blepharospasm revealed by fMRI. Neurology, 60: 1738-1743.
25. STOURAC P, KAOANKA Z, PALYZA V. (2001). Paraneoplastic neurological syndromes - patients' cohort profile in Czech Republic. Acta Neurol Scand, 104: 72-77.
26. SUTTON IJ, BARNETT MH, WATSON JD, ELL JJ, DALMAU J. (2002). Paraneoplastic brainstem encephalitis and anti-Ri antibodies. J Neurol, 249: 1597-1598.
27. TARDY J, BENOUAICH A, PAYOUX P, OKSMAN F, CLANET M. (2003). Pseudo-PSP d'évolution fulgurante dans le cadre d'un syndrome paranéoplasique à anticorps anti-Ri d'un cancer du sein. Rev Neurol (Paris), 159: 25108.
28. VOLTZ R. (2002). Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol, 1: 294-305.
29. WIRTZ PW, SILLEVIS SMITT PA, HOFF JI et al. (2002). Anti-Ri antibody positive opsoclonus-myoclonus in a male patient with breast carcinoma. J Neurol, 249: 1710-1712.